HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

José-Ángel Hernández-Rivas Selected Research

TNF Receptor-Associated Factor 3

1/2022TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


José-Ángel Hernández-Rivas Research Topics

Disease

9COVID-19
01/2024 - 01/2020
6B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2024 - 11/2020
6Neoplasms (Cancer)
11/2023 - 10/2021
4Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
09/2022 - 01/2019
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2021 - 08/2017
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
11/2018 - 07/2015
1Prostatic Neoplasms (Prostate Cancer)
11/2023
1Melanoma (Melanoma, Malignant)
11/2023
1Frailty
09/2023
1Sinusitis
04/2023
1Lung Diseases (Lung Disease)
04/2023
1Rhinitis
04/2023
1Obesity
04/2023
1Anosmia
04/2023
1Fever (Fevers)
04/2023
1Virus Diseases (Viral Diseases)
01/2023
1Circulating Neoplastic Cells
11/2022
1Non-Hodgkin Lymphoma (Lymphosarcoma)
09/2022
1Hematologic Diseases (Blood Diseases)
09/2022
1Infections
09/2022
1Disease Progression
01/2022
1Lymphadenopathy
12/2021
1Hodgkin Disease (Hodgkin's Disease)
12/2021
1Coinfection
10/2021
1Cardiotoxicity
01/2021
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2021
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2021
1Composite Lymphoma
11/2020
1Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
11/2020
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2019
1Neutropenia
08/2017
1Rheumatoid Arthritis
08/2017

Drug/Important Bio-Agent (IBA)

5Rituximab (Mabthera)FDA Link
11/2023 - 08/2017
5VaccinesIBA
04/2023 - 12/2021
5ibrutinibIBA
09/2022 - 01/2019
3nirmatrelvir and ritonavir drug combinationIBA
01/2024 - 04/2023
3Biomarkers (Surrogate Marker)IBA
01/2024 - 04/2021
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2023 - 08/2017
3Monoclonal AntibodiesIBA
01/2023 - 09/2022
2Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA
01/2024 - 11/2020
2Antiviral Agents (Antivirals)IBA
10/2023 - 12/2022
2Messenger RNA (mRNA)IBA
12/2022 - 12/2021
2Agammaglobulinaemia Tyrosine KinaseIBA
01/2022 - 01/2020
2CT-P10IBA
01/2021 - 08/2017
2Biosimilar PharmaceuticalsIBA
01/2021 - 08/2017
2Prednisone (Sone)FDA LinkGeneric
01/2021 - 08/2017
2Vincristine (Oncovin)FDA LinkGeneric
01/2021 - 08/2017
2Tyrosine Kinase InhibitorsIBA
11/2018 - 07/2015
1N-(2-cyanoethylene)urea (BA 1)IBA
01/2024
1remdesivirIBA
01/2024
1N-methyl-valyl-amiclenomycin (BA 2)IBA
01/2024
1Immunoglobulins (Immunoglobulin)IBA
11/2023
1fludarabineIBA
11/2023
1molnupiravirIBA
10/2023
1Antineoplastic Agents (Antineoplastics)IBA
09/2023
1Chimeric Antigen ReceptorsIBA
01/2023
1AntibodiesIBA
09/2022
1Adrenal Cortex Hormones (Corticosteroids)IBA
09/2022
1TNF Receptor-Associated Factor 3IBA
01/2022
1Bendamustine HydrochlorideFDA Link
01/2022
1Phosphotransferases (Kinase)IBA
01/2022
1Lenalidomide (CC 5013)FDA Link
01/2022
1ChAdOx1 nCoV-19IBA
12/2021
1COVID-19 VaccinesIBA
12/2021
1serum P-component (CIt)IBA
10/2021
1liposomal doxorubicin (Doxil)FDA Link
01/2021
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021
1Cytarabine (Cytosar-U)FDA LinkGeneric
01/2019
1AnthracyclinesIBA
01/2019
1Imatinib Mesylate (Gleevec)FDA Link
07/2015

Therapy/Procedure

5Therapeutics
09/2022 - 01/2020
2Stem Cell Transplantation
01/2024 - 11/2020
1Blood Transfusion (Blood Transfusions)
05/2021
1Intravenous Infusions
08/2017